The ARYx mission is to make proven therapies safer. By applying its retrometabolic approach to pharmaceutical discovery and development, ARYx intends to serve patients by fundamentally improving the safety of oral therapies in large, chronic markets while maintaining their efficacy. To optimize shareholder value, ARYx's goal is to be a profitable company with a continuing pipeline of products, balancing risk against rewards through collaborations with pharmaceutical partners.
Recent Releases
Mar 4, 2010
ARYx to Present at Cowen and Company Annual Health Care Conference
Feb 18, 2010
ARYx Therapeutics Retains Cowen and Company To Explore Strategic Options
